Abstract
Marcellomycin is a pyrromycinone glycoside isolated by fractionation of the bohemic acid complex, an anthracycline mixture obtained from fermentations of Actinospohangium sp. (1). Its chemical structure is closely related to that of aclacinomycin A (Fig. 1). The antitumor effect of the drug has been ascribed, at least in part, to its ability to inhibit nucleolar RNA synthesis (2). In Novikoff hepatoma ascites cells, this inhibition requires concentrations more than 1000-fold lower than those necessary to inhibit DNA synthesis whereas doxorubicin as well as pyrromycin inhibit DNA and nucleolar RNA synthesis at similar concentrations (3).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Nettleton DE Jr, Bradner WT, Bush JA, Coon AB, Moseley JE, Myllymaki RW, O’Herron FA, Schreiber RH, Vulcano AL. 1977, New antitumor antibiotics: Musettamycin and marcellomycin from bohemic acid complex. J. Antibiotics, 30, 525–529.
Du Vernay VH, Essery JM, Doyle TW, Bradner WT, Crooke ST. 1979. The antitumor effects of anthracyclines. The importance of the carbometoxy-group at position-l0 of marcellomycin and rudolfomycin. Molecular Pharmacol., 15, 341–356.
Crooke ST, Duvernay VH, Galvan L, Prestayko AW. 1978. Structureactivity relationships of anthracyclines relative to effects on macromolecular syntheses. Molecular Pharmacol., 14, 290–298.
Bradner WT, Rose WC. 1980. Antitumor testing in animals. In: Anthracyclines: Current Status and New Developments. Crooke ST and Reich SD (Eds). Academic Press, New York, pp. 125–140.
Bradner WT, Misiek M. 1977. Bohemic acid complex. Biological characterization of the antibiotics, musettamycin and marcellomycin. J. Antibiotics, 30, 519–522.
Reich SD, Bradner WT, Rose WC, Schurig JE, Madissoo H, Johnson OF, Du Vernay VH, Crooke ST. 1980. Marcellomycin. In: Anthracyclines: Current Status and New Developments. Crooke ST and Reich SO (Eds) Academic Press, New York, pp. 343–364.
Hirth RS. 1980. Other toxicities associated with anthracyclines in animal systems. In: Anthracyclines: Current Status and New Developments. Crooke ST and Reich SD (Eds). Academic Press, New York, pp. 221–240.
Marsh JC. 1981. Bone marrow colony forming cell sensitivity to carminomycin, marcellomycin and spirogermanium. Proc. Am. Assoc Cancer Res. and ASCO, 22, 241.
Schurig JE, Bradner WT, Huftalen JB, Doyle GJ. 1980. Screening anthracyclines for side effects in mice. In: Anthracyclines: Current Status and New Developments. Crooke ST and Reich SO (Eds). Academic Press, New York, pp. 141–149.
Buyniski JP, Hirth RS. 1980. Anthracycline cardiotoxicity in the rat. In: Anthracyclines: Current Status and New Developments. Crooke ST and Reich SO (Eds) Academic Press, New York, pp. 157–170.
Pike BL, Robinson WA. 1970. Human bone marrow colony growth in agargel. J. Cell Physiology, 76, 77–84.
Rozencweig M, Von Hoff DO, Staquet MJ, Schein PS, Penta JS, Goldin A, Muggia FM, Freireich EJ, De Vita VT Jr. 1981. Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials, 4, 21–28.
WHO Handbook for Reporting Results of Cancer Treatment. WHO Geneva, 1979.
Rozencweig M, Von Hoff DO, Cysyk RL, Muggia FM. 1979. m-AMSA and PALA: Two new agents in cancer chemotherapy. Cancer Chemother. Pharmacol., 3, 135–141.
Ogawa M, Inagaki J, Horikoshi N, Inoue K, Chinen T, Ueoka H, Nagura E. 1979. Clinical study of aclacinomycin A. Cancer Treat. Rep., 63, 931–934.
Casper E, Gralla RJ, Young CW. 1981. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule. Cancer Res., 41, 2417–2420.
Egorin MJ, Van Echo DA, Whitacre MY, Fox BM, Aisner J, Wiernik PH, Bachur N. 1981. A phase I trial of aclacinomycin-A (ACM-A). Proc. Am. Assoc. Cancer Res. and ASCO, 22, 353.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Martinus Nijhoff Publishers, The Hague
About this chapter
Cite this chapter
Rozencweig, M. et al. (1982). Preliminary Experience with Marcellomycin: Preclinical and Clinical Aspects. In: Muggia, F.M., Young, C.W., Carter, S.K. (eds) Anthracycline Antibiotics in Cancer Therapy. Developments in Oncology, vol 10. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7630-6_50
Download citation
DOI: https://doi.org/10.1007/978-94-009-7630-6_50
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-7632-0
Online ISBN: 978-94-009-7630-6
eBook Packages: Springer Book Archive